Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05198245 · ClinicalTrials.gov registry record
Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
A clinical trial of Migraine, sponsored by Pfizer.
- Active
- Registry status
- 1
- Enrollment target
- 1
- Study location
NCT05198245 is a study of Migraine that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 1 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05198245, a study of Migraine, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the risk of pregnancy and infant outcomes among women with migraine exposed to rimegepant during pregnancy and in two rimegepant unexposed comparator groups.
Conditions Studied
Interventions
- OTHER No intervention
- DRUG Rimegepant
- DRUG Various
Study Locations (1)
New York
- Pfizer - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-12-15 |
| Est. Completion | 2028-04-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05198245
The ClinicalTrials.gov registry entry for NCT05198245 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (100% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 3 interventions - of which No intervention is the first listed.
NCT05198245 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05198245 about?
NCT05198245 is a clinical study titled "Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy". The purpose of the study is to evaluate the risk of pregnancy and infant outcomes among women with migraine exposed to rimegepant during pregnancy and in two rimegepant unexposed comparator groups.
What is the current status of trial NCT05198245?
This trial is currently active not recruiting. The enrollment target is 1 participants. The study started on 2021-12-15. Estimated completion is 2028-04-17.
What conditions does trial NCT05198245 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT05198245?
The interventions under investigation include: No intervention (OTHER), Rimegepant (DRUG), Various (DRUG).
Who is sponsoring clinical trial NCT05198245?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05198245 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents
RECRUITING
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
Mechanistic Studies of Psilocybin in Headache Disorders
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.